Standard Postoperative Analgesics

Phase 3Small molecule

Standard Postoperative Analgesics is one of 2 small molecule programs targeting Erector Spinae Plane Block. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Erector Spinae Plane BlockRecruiting

Erector Spinae Plane BlockPhase 3

Recruiting

Competition

Competitive Landscape

4 competitors in Erector Spinae Plane Block

#DrugCompanyPhaseTrials

Naropin

FFresenius Kabi Oncology Ltd.

Phase 3

8 2

Standard Postoperative Analgesics

EE-DA Hospital

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Erector Spinae Plane Block

NCT07666178

Clinical

Trials by Indication[1]

Post Operative Pain1 trial

2% Lidocaine Gel in Reducing Postoperative Pain Following Haemorrhoidectomy

Recruiting·—·N/A·NCT06420388·400 enrolled

Erector Spinae Plane Block1 trial

Continuous Erector Spinea Plane Block in Patients Undergoing Coronary Artery By-pass Graft Surgery.

Recruiting·IInstituto do Coracao·Phase 3·NCT07666178·78 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Standard Postoperative Analgesics. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Standard Postoperative Analgesics compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Standard Postoperative Analgesics. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — E-DA Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: EE-DA Hospital

Standard Postoperative Analgesics

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Post Operative Pain1 trial

Erector Spinae Plane Block1 trial

References

Drug Info

Quick Facts

Related News